Nisa Investment Advisors LLC Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

Nisa Investment Advisors LLC raised its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 166.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,108 shares of the company's stock after buying an additional 21,330 shares during the period. Nisa Investment Advisors LLC's holdings in Moderna were worth $967,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. raised its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares during the period. Commonwealth Equity Services LLC raised its holdings in shares of Moderna by 0.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after purchasing an additional 345 shares during the period. Deseret Mutual Benefit Administrators raised its holdings in shares of Moderna by 53.3% in the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares during the period. Parallel Advisors LLC raised its holdings in shares of Moderna by 11.4% in the 1st quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock worth $125,000 after purchasing an additional 451 shares during the period. Finally, Signaturefd LLC raised its holdings in shares of Moderna by 17.4% in the 4th quarter. Signaturefd LLC now owns 3,618 shares of the company's stock worth $150,000 after purchasing an additional 535 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on MRNA shares. Royal Bank Of Canada lowered their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Evercore ISI lowered their price target on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Cowen started coverage on shares of Moderna in a report on Sunday. They issued a "hold" rating on the stock. Barclays reaffirmed an "equal weight" rating on shares of Moderna in a report on Sunday. Finally, UBS Group reduced their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Moderna has an average rating of "Hold" and an average target price of $46.61.

Moderna Price Performance

MRNA opened at $32.87 on Tuesday. The company has a fifty day moving average price of $27.21 and a 200-day moving average price of $31.09. The firm has a market capitalization of $12.71 billion, a P/E ratio of -3.77 and a beta of 1.84. Moderna, Inc. has a one year low of $23.15 and a one year high of $127.20.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same period in the previous year, the business earned ($3.07) earnings per share. The firm's quarterly revenue was down 35.3% compared to the same quarter last year. On average, analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.